Why these ASX growth shares could rise 30%+

Analysts think these shares are undervalued. Let's see what they are saying.

| More on:
A man sees some good news on his phone and gives a little cheer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you have a penchant for ASX growth shares like I do, then read on!

That's because the two in this article have not only been named as buys but have been tipped to rise at least 30% from current levels. Here's what analysts are saying about them:

Life360 Inc (ASX: 360)

The team at Goldman Sachs thinks that this location technology company could be a quality ASX growth share to buy now.

It has a buy rating and $27.00 price target on its shares. This suggests that upside of 30% is possible for investors between now and this time next year.

The broker likes Life360 due to its huge total addressable market (TAM) and significant user monetisation opportunity. It explains:

We estimate Life360 is exposed to a US$12bn global TAM with a large opportunity to expand its product suite, grow average revenue per paying circle (ARPPC), increase payer conversion, and lift penetration rates outside of the US. The company has demonstrated its pricing power and is now exploring the latent monetisation opportunity of its >60mn user base via advertising.

Goldman also highlights that its shares are undervalued compared to peers. It adds:

 Life360's Subscription business currently trades at a discount to global subscription app peers when adjusting for its superior growth outlook. We see scope for re-rating as Life360 demonstrates operating leverage, ongoing subscription growth and user monetisation via ads. We are Buy rated on Life360.

Pro Medicus Limited (ASX: PME)

Bell Potter thinks that this health imaging technology company could be an ASX growth share to buy.

Its analysts have put a buy rating and $280.00 price target on its shares. Based on its current share price, this implies potential upside of 33% over the next 12 months.

Commenting on the company, the broker said:

Pro medicus is a leading health imaging IT provider. It's leading product is the Visage 7 Enterprise Viewer (the Visage Viewer). It is an essential component of a modern PACS with its main advantage being speed. Using this system the radiologist is able to view medical images from all major modalities at lightning fast speed including prior exams.

Visage 7 is the fastest, most versatile viewing software on the market and it is the key reason why Pro medicus has been successful in winning numerous high profile hospital contracts in the US, ahead of some of the largest global names in the industry.

Motley Fool contributor James Mickleboro has positions in Life360 and Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Life360. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Person pointing at an increasing blue graph which represents a rising share price.
Growth Shares

2 ASX growth shares to snap up while they're still down

Brokers see plenty of upside for these mainstay sector picks.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Growth Shares

Why these ASX growth stocks could be much bigger in 2030 than today

These stocks have long growth runways and strong business models.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Growth Shares

3 incredible ASX growth shares to buy and hold forever in 2026

True long-term investing means owning businesses you’d be happy to hold through volatility, uncertainty, and decades of change.

Read more »

Happy work colleagues give each other a fist pump.
Growth Shares

2 shares to buy hand over fist before the ASX 200 soars higher in 2026

These shares are highly rated by brokers for a reason. Here's what you need to know about them.

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Broker Notes

Experts rate these 2 ASX shares as buys this month!

Leading analysts say these stocks are a buy.

Read more »

Happy healthcare workers in a labs
Technology Shares

Prediction: CSL shares could soar past $270 in 2026

Here's what to expect from the Australian-based global biotechnology company this year.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

2 unstoppable ASX 200 stocks to buy in 2026 and hold forever

These blue chips could have very bright futures. Do you own them?

Read more »

A man sees some good news on his phone and gives a little cheer.
Growth Shares

5 incredible ASX growth stocks to buy for 2026

These growth stocks could be well-positioned for the long-term.

Read more »